title: Urinary excretion of acid-soluble peptides in children with Duchenne muscular dystrophy.
abstract: In order to investigate the validity of the hypothesis that acid-soluble peptides (ASP) in urinary excreta can be applied as an index of the protein catabolism of the whole body, we measured the urinary excretion of ASP in 46 normal children and in 18 children with Duchenne muscular dystrophy (DMD), in which continuous breakdown of skeletal muscle protein is presumed. The mean value of ASP in the children with DMD was significantly higher than that in normal controls. The concentration of ASP was correlated with that of 3-methylhistidine (3MH), which has been proposed as an index of muscle breakdown. This finding indicates that urinary ASP reflects the catabolism of body proteins. No correlation was observed between the concentration of ASP and that of 1-methylhistidine (1MH), which is used as an objective index of meat and fish ingestion. After the administration of bestatin, an inhibitor of leucine aminopeptidase, for 9 months, the urinary ASP concentration of children with DMD increased markedly. This increase is thought to have been directly caused by the bestatin itself. Urinary ASP is therefore apparently a more conveniently applied index of protein catabolism than is urinary 3MH, which requires the application of several restrictions. However, it should not be applied when the effect of bestatin administration is evident.
authors.affiliation: Faculty of Science of Living, Osaka City University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Hirano
authors.forename: Y
authors.initials: Y
authors.lastname: Sakamoto
mesh_terms: D000293:Adolescent; D000367:Age Factors; D000626:Aminopeptidases / Q000037:antagonists & inhibitors; D000970:Antineoplastic Agents; D002648:Child; D002675:Child, Preschool; D002854:Chromatography, Paper; D005260:Female; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000652:urine; D008297:Male; D008762:Methylhistidines / Q000652:urine; D018482:Muscle, Skeletal / Q000378:metabolism / Q000503:physiopathology; D009136:Muscular Dystrophies / Q000188:drug therapy / Q000503:physiopathology / Q000652:urine*; D010455:Peptides / Q000652:urine*; D010919:Placebos; D011506:Proteins / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D008762:Methylhistidines; D010455:Peptides; D010919:Placebos; D011506:Proteins; D000626:Aminopeptidases; D007930:Leucine; C012211:ubenimex; C028118:3-methylhistidine